The Acomplia Paradox: Primary Care Drug, Targeted Population

As Acomplia is launched across Europe, Sanofi Aventis' challenge is less about promoting the drug, than about limiting its use within the appropriate target group.

Melanie Senior

Sanofi-Aventis’ rimonabant (Acomplia) was never going to fit neatly into any of the industry’s pre-defined categories. Approved in Europe in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo